Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Central Nervous System Neoplasms 6Glioblastoma 4Brain Neoplasms 4Pancreatic Neoplasms 3Colonic Neoplasms 3Stomach Neoplasms 2Sarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neuroblastoma 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma 2Gliosarcoma 2Gallbladder Neoplasms 2Colorectal Neoplasms 2Choroid Plexus Neoplasms 2Carcinoma, Hepatocellular 2Astrocytoma 2Vipoma 1Thyroid Neoplasms 1Somatostatinoma 1Retinoblastoma 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Osteosarcoma 1

Interventions

trifluridine tipiracil drug combination 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenomatous Polyposis Coli × Leucovorin × CNS × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡